László Piros

László Piros

Auto-generated profile, based on publicly available information

László Piros

Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Transplantation Proceedings
Verified
Journal Article
Closed access
GVG. Végsö
G. Végsö
ÉTÉ. Toronyi
É. Toronyi
MHM. Hajdu
M. Hajdu
LPL. Piros
L. Piros
DGD. Görög
D. Görög
RLR.M. Langer
R.M. Langer

4 October 2021 in Transplantation
Verified
Journal Article
Open access
VAVolker Assfalg
Volker Assfalg
GMGregor Msc Miller
Gregor Msc Miller
FSFelix Stocker
Felix Stocker
MMMarieke van Meel
Marieke van Meel
TGTiny Groenevelt
Tiny Groenevelt
UHUwe Heemann
Uwe Heemann
Background.: At Eurotransplant (ET), kidneys are transferred to “rescue allocation” (RA), whenever the standard allocation (SA) algorithms Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP) fail. We analyzed the outcome of RA. Methods.: Retrospective patient clinical and demographic characteristics association analyses were performed with graft outcomes for 2422 recipients of a deceased donor renal transplantation (DDRT) after RA versus 25 481 after SA from 71 centers across all ET countries from 2006 to 2018. Results.: Numbers of DDRTs after RA increased over the time, especially in Germany. RA played a minor role in ESP versus ETKAS (2.7% versus 10.4%). RA recipients and donors were older compared with SA recipients and donors, cold ischemia times were longer, waiting times were shorter, and the incidence of primary nonfunction was comparable. Among ETKAS recipients, HLA matching was more favorable in SA (mean 3.7 versus 2.5). In multivariate modeling, the incidence of graft loss in ETKAS recipients was reduced in RA compared with SA (subdistribution hazard ratio, 0.80; 95% confidence interval [0.70-0.91], P < 0.001), whereas other outcomes (mortality, death with functioning graft (DwFG)) were not significantly different. None of the 3 outcomes were significantly different when comparing RA with SA within the ESP program. Conclusions.: Facing increased waiting times and mortality on dialysis due to donor shortage, this study reveals encouragingly positive DDRT outcomes following RA. This supports the extension of RA to more patients and as an alternative tool to enable transplantation in patients in countries with prohibitively long waiting times or at risk of deterioration.

17 January 2021 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
GTGábor Telkes
Gábor Telkes
LPLászló Piros
László Piros
JSJózsef Szabó
József Szabó
GHGergely Huszty
Gergely Huszty
KEKatalin Eitler
Katalin Eitler
LKLászló Kóbori
László Kóbori
Background: In the Eurotransplant, 12.6% of kidney transplantations are a repeat procedure. Third transplants are significantly more complex than first and second ones. We compared the results of first (PRT) versus third (TRT) transplantations. Methods: Between 2011 and 2016, we performed 779 deceased donor adult kidney transplantations, 14.2% out of them were second, 2.6% (20) third, and 0.3% fourth. We compared the pre-, intra-, and postoperative data, kidney function, and survival rate. Results: Recipients of TRT were younger (53.4 vs. 47.3 p = 0.02). HCV infection rate (20%, p = 0.00) is ten times higher. The operation time is longer (132 vs. 152 min, p = 0.02), and delayed graft function is much more frequent (22.4% vs. 60%, p = 0.00). Induction therapy was given to every TRT (7.9% vs.100%), but as a result, the rejection rate was the same (~ 15%). Hospital stay is a week longer. Patient’s survival at 1, 3, and 5 years for PRT is 96.4%, 93.9%, and 91.2% and for TRT is 90%, 85%, and 78.4%, respectively (p = 0.023). TRT’s odds ratio of fatal outcome is 4.35 (1.5–12.5). Graft survival at 1, 3, and 5 years for PRT is 93.1%, 91.4%, and 90.3% and for TRT is 75%, 75%, and 75%, respectively (p = 0.020). TRT’s odds ratio of graft loss is 3.14 (1.1–8.9). Of PRT 85.76%, out of PRT 85.76%, while out of TRT 60% live with a functioning graft, p=0.00149. Conclusion: In a third transplant, both graft and patient survival are significantly inferior to primer ones. Careful selection is required to minimize the patient risk and graft loss.

1 December 2013 in Transplantation Proceedings
Verified
Journal Article
Closed access
Henrik C. BäckerHenrik C. Bäcker
Henrik C. Bäcker
LPL. Piros
L. Piros
RLR.M. Langer
R.M. Langer

13 January 2026 in Imaging
Verified
Journal Article
Open access
DKDavid Adam Korda
David Adam Korda
BTBoglárka Tóth
Boglárka Tóth
DHDenes B. Horvathy
Denes B. Horvathy
SCSándor Czibor
Sándor Czibor
DNDomonkos Nádasdy-Horváth
Domonkos Nádasdy-Horváth
ABAndrás Bibok
András Bibok
We present a case demonstrating the potential of radioembolization with Ho-166-labelled microparticles as an effective bridging therapy for hepatocellular carcinoma (HCC) in a 70-year-old male patient with liver cirrhosis awaiting liver transplantation. The patient received a calculated dose of 3 GBq of Ho-166 microspheres, which were selectively administered intra-arterially to the target area during the radioembolization procedure. Post-treatment dosimetry revealed an average tumor absorbed dose of 332 Gy. Contrast-enhanced CT scan performed one month later revealed a necrotic, non-enhancing area at the tumor site, indicating a complete response. The patient successfully underwent liver transplantation 2.5 months after radioembolization. This case suggests that Ho-166 radioembolization is a promising locoregional therapy for HCC, particularly for patients requiring a bridging approach to transplantation.

27 October 2026 in Transplantation Proceedings
Verified
Journal Article
Closed access
BRBalázs Rózsa
Balázs Rózsa
BPBalázs Pőcze
Balázs Pőcze
JKJános Kovács
János Kovács
ÁRÁdám Remport
Ádám Remport
LWLászló Wágner
László Wágner
LPLászló Piros
László Piros